Skip to main content

Table 1 Alternative splicing signatures associated with overall survival in patients with BRCA

From: Characterization of alternative splicing events and prognostic signatures in breast cancer

AS type Formula HR (95% CI) AUC
AA (BRPF3|75960|AA×-6.16)+(TMEM25|19023|AA×-2.96)+(TMEM25|19017|AA×-2.3)+(EIF4G3|957|AA×2.01)+(SLC38A6|27787|AA×-1.91)+(PNPLA8|81412|AA×-2.33)+(SAFB|46852|AA×-3.57)+(PJA1|89360|AA×1.47)+(CAMTA2|38638|AA×-1.34)+(DBF4|80345|AA×10.15)+(SMG7|9181|AA×3.66)+(PSMD13|13632|AA×-0.61)+(ELF1|25724|AA×-22.6)+(ZNF268|25354|AA×10.09)+(SEC24D|70448|AA×3.56)+(PKMYT1|33330|AA×-1.27)+(ATXN3|28923|AA×-15.55)+(GGT5|61393|AA×-2.62) 6.369 (3.753-10.807) 0.697
AD (POMT1|87937|AD×-1.65)+(ENOPH1|69708|AD×-3.16)+(FCF1|28425|AD×-3.4)+(DCAF11|26842|AD×-5.4)+(OBSL1|57731|AD×-4.41)+(ARSA|62901|AD×2.52)+(HNRNPUL1|50039|AD×-1.14)+(FRMD6|27515|AD×-1.89)+(RNF41|22407|AD×3.64)+(TVP23C|39359|AD×-4.64)+(FBXL12|47433|AD×2.69)+(C7orf49|81873|AD×-2.3)+(SEC31A|100880|AD×6.21)+(NKG7|51322|AD×-18.81)+(PTBP3|87243|AD×2.33)+(BCL2L11|54966|AD×-2.19)+(PDGFC|70954|AD×-8.91) 5.365 (3.172-9.074) 0.751
AP (ANK3|11845|AP×1.14)+(HSPBP1|52052|AP×-3.16)+(RPS6KA1|1282|AP×2.6)+(NR1H3|15695|AP×-1.42)+(SH3BP2|68591|AP×1.82)+(KLF11|52654|AP×3.89)+(APOC2|50372|AP×-4.67)+(MEF2A|32713|AP×6.02)+(RAD21|84981|AP×-5.01)+(MOK|29361|AP×-3.24)+(TOP1MT|85413|AP×-9.73)+(SPAG9|42493|AP×1.79) 3.112 (2.000-4.844) 0.703
AT (USH2A|9805|AT×-8.17)+(CYP4B1|2832|AT×-3.23)+(EYS|76614|AT×-4.42)+(DAPL1|55687|AT×-0.77)+(CDK15|56923|AT×-3.48)+(TNFRSF13B|39449|AT×-1.13)+(ATRNL1|13220|AT×1.57)+(CLEC3A|37670|AT×0.56)+(EFCAB13|42070|AT×-1.38)+(CHRNA1|56036|AT×-5.08)+(FAM184A|77360|AT×3.36)+(C3orf55|67409|AT×1.55) 3.877 (2.423-6.203) 0.72
ES (PARPBP|24031|ES×-0.97)+(NCOR1|39424|ES×-3.52)+(UBE2V1|59762|ES×-4.81)+(HNRNPM|94942|ES×-5.83)+(ITGB5|100223|ES×-10.88)+(CNST|10497|ES×-4.78)+(SCLY|58203|ES×-4.27)+(SUV420H1|17300|ES×-7.95)+(ARHGAP12|11155|ES×-2.64)+(HARS2|73762|ES×-11.75)+(BTN3A2|75634|ES×-2.49)+(FDFT1|82653|ES×-1.36)+(RCSD1|8870|ES×-3.22)+(TDG|24084|ES×-3.41)+(FCGR2B|8681|ES×-2.17)+(BCL2L11|54967|ES×-1.75)+(ENOSF1|44469|ES×-4.23) 5.327 (3.240-8.756) 0.769
ME (COPS5|115459|ME×1.67)+(GOLT1B|92984|ME×1.41)+(GRB10|79717|ME×-0.81)+(CPSF7|99751|ME×-1.12)+(SORBS2|71377|ME×2.69)+(SRGAP1|93242|ME×2.17)+(PTK2|98071|ME×2.21) 2.853 (1.833-4.440) 0.667
RI (PRX|49900|RI×1.3)+(COPZ1|22159|RI×-2.86)+(PHTF1|4284|RI×1.73)+(SV2B|32540|RI×-4.98)+(CHTF8|37263|RI×-9.28)+(AK9|77206|RI×-3.77)+(GLI4|85407|RI×-1.26)+(MTF2|3771|RI×-5.62)+(PCSK7|18902|RI×-2.86)+(PDGFC|70956|RI×-9.44)+(HYAL1|64998|RI×-2.72)+(DERL3|61334|RI×1.31)+(CD59|14911|RI×-9.36)+(KIAA0895L|36957|RI×6.12) 4.667 (2.856-7.626) 0.767
ALL (PARPBP|24031|ES×-0.91)+(NCOR1|39424|ES×-5.48)+(COPZ1|22159|RI×-2.44)+(ANK3|11845|AP×0.62)+(ITGB5|100223|ES×-22.45)+(PHTF1|4284|RI×2.17)+(HSPBP1|52052|AP×-3.02)+(TCF12|30783|AP×1.47)+(RPS6KA1|1282|AP×2.47)+(CNST|10497|ES×-3.92)+(TMEM25|19023|AA×-2.99)+(TMEM25|19017|AA×-1.08)+(BTN3A2|75630|ES×-2.65) 5.175 (3.093-8.659) 0.801
  1. AS alternative splicing, HR hazard ratio, AUC area under curve, AA alternate acceptor, AD alternate donor sites, AP alternate promoters, AT alternate terminators, ES exon skips, ME mutually exclusive exons, RI retained introns, ALL all types